One Sentence Summary: Specific, covalent, mechanism-based inhibitors of influenza neuraminidase function as potent (IC 50 = 1 -10 nM) antiviral agents in vitro and protect mice against infection.
Abstract: Influenza antiviral agents play important roles in modulating disease severity and in controlling pandemics while vaccines are prepared, but the development of resistance to agents like the commonly used neuraminidase inhibitor Tamiflu may limit their future utility. We report here a completely new class of specific, mechanism-based anti-influenza drugs that function via the formation of a highly stabilized covalent intermediate in the neuraminidase enzyme, and confirm this mode of action via structural and mechanistic studies. These compounds function not only in cell-based assays, but also in animal models, with efficacies comparable to that of Relenza and with broad spectrum activity against drug-resistant strains in vitro. With their great structural similarity to the natural substrate, and their novel mode of action based upon the enzyme mechanism, this class of drug should be less prone to resistance development, offering a new approach to the control of influenza.
Main Text:
The envelope of the influenza virus contains two immunodominant glycoproteins, hemagglutinin (HA) and neuraminidase (NA) , that play key roles in viral infection and spread.
HA effects attachment of the virus to the host cell via its interaction with surface sialic acids, thereby initiating entry. Once the virus has replicated, the NA cleaves sialic acids from the viral and cell surfaces, allowing the virus progeny to spread to uninfected cells. The specific antigenic properties of the different HAs and NAs are used to classify influenza type A viruses into subtypes (H1-17 and N1-9). These in turn can be categorized into two groups on the basis of neuraminidase phylogeny: Group 1 contains N1, N4, N5 and N8, while Group 2 contains N2, N3, N6, N7 and N9. Based on the notion that potent and specific viral NA inhibitors should function to reduce viral spread, structure-based inhibitor design programs have produced two widely used anti-influenza drugs, zanamivir (Relenza ® ) and oseltamivir (Tamiflu ® ) (Fig. 1A ).
Oseltamivir figured prominently in the control of the recent H1N1 pandemic. The initial design of these drugs was based upon the mimicry of the flattened transition state conformation of the sugar through incorporation of an endocyclic alkene within a carbocycle (oseltamivir) or a pyranose ring (zanamivir) (1) . Specificity for the influenza enzyme over other neuraminidases, along with additional affinity, was provided by incorporation of a guanidinium or ammonium substituent at the position corresponding to C-4 of the natural substrate to interact with a highly conserved anionic pocket at that location in the active site. These broad spectrum influenza drugs are active against NAs from group 1 and 2 influenza A strains as well as influenza B.
We are now seeing the emergence of drug-resistant strains, particularly against the more widely used and structurally divergent drug oseltamivir. Mutations can be both drug-and influenza subtype-specific. The most commonly seen mutation in viruses with the N1 subtype is H275Y which interferes with binding of the isopentyl side chain of oseltamivir, but still permits binding of zanamivir and the natural substrate. Mutations most commonly detected in clinical isolates with the N2 subtype include R292K (2-4) and E119V (3, 4) . Like the H275Y, the R292K precludes full rotation of the E276 necessary to create the hydrophobic pocket that accommodates the pentyl side-chain of oseltamivir (5) . In contrast, E119V confers oseltamivir specific resistance due to altered interactions with the 4-amino group. E119A,D,G mutations seen in vitro (6, 7) affect binding of oseltamivir and/or zanamivir, demonstrating the critical nature of the interactions of C-4 amino or guanidino group for high affinity binding. Some of the recent mutations seen in pandemic H1N1 viruses, including I223R, confer reduced sensitivity to both inhibitors (8) (9) (10) . The emergence of these mutant strains highlights an urgent need for new classes of NA inhibitors that differ minimally in structure from the parent sialic acid, given that the development of resistance to structurally conservative, mechanism-based inhibitors should be a much less probable event (5). With the knowledge that that the influenza NAs employ a covalent mechanism, we embarked on a program to explore these 2,3-difluoro sialic acids (DFSAs) as a possible new class of mechanism-based influenza therapeutics that inhibit by covalently blocking the active site. This is an attractive approach since not only can the initial affinity of the drug (K i ) be optimized, but also, the relative rate constants for formation (k i ) and hydrolysis (k hydr ) of the trapped intermediate, with the objective being to optimize the ratio of k i /k hydr . Such a strategy has worked well previously for the β-lactam antibiotics, and may provide particularly favorable pharmacokinetic behavior in this situation. Indeed covalent drugs are regaining respect, with three of the top-selling drugs in the U.S. being covalent inhibitors of their targets (14) . Key improvements required to convert 1 into a useful drug candidate are therefore to introduce selectivity for the viral NA over host enzymes and to drastically reduce rates of turnover (k hydr ).
Since the incorporation of an equatorial cationic nitrogen substituent at the site equivalent to OH-4 of sialic acid provided a substantial affinity boost within zanamivir and oseltamivir, it was of interest to synthesize versions of 1 bearing amine (Am) and guanidine (Gu) substituents at C-4.
Not only might these electron-withdrawing substituents improve the initial affinity and the specificity for the influenza enzyme, but also turnover of the intermediate may be further slowed, due both to the additional stabilization of the bound intermediate provided through improved interactions with the enzyme, and to the added inductive effect of the substituent on the reaction transition state. The effects of axial (ax) or equatorial (eq) stereochemistry of F3 on inhibitory behavior were also explored.
Synthesis of the protected diastereomeric 3-axial and 3-equatorial-2,3-difluoro-4-azido neuraminic acids as key intermediates was achieved by Selectfluor™ hydroxyfluorination of 2,4-dideoxy-2,3-didehydro-4-azido-N-acetylneuraminic acid (4-azido-DANA) (15) followed by installation of an equatorial fluorine at C-2 using diethylaminosulfur trifluoride (DAST). The lead candidates shown in Table 1 , FaxAmDFSA (2), FaxGuDFSA (3), FeqAmDFSA (4) and FeqGuDFSA (5) were then prepared by reduction or reductive guanidylation, followed by deprotection. Full synthetic details and product characterization are provided as Supplementary
Materials.
Selective inhibition of influenza virus NA in vitro
Kinetic parameters for inactivation and reactivation of N1, N2 and N9 NAs, as representatives of the Group 1 and Group 2 enzymes, by 2 -5 are presented in Tables 1 and S4, along with parameters for the parent 2,3-difluorosialic acid 1 with the N9 NA. As noted, inactivation by 1 was too fast, even at 4 o C, for individual parameters of the inactivation rate (k i ) and binding (K i ) constants to be measured, thus only the second order rate constant (k i /K i ) was determined. Rate constants for turnover by hydrolysis (k hydr ) were determined by monitoring the time course of reactivation of dialyzed, inactivated enzyme, and fitting the data to a first order expression. First order rate constants for inactivation and reactivation are also expressed in the form of half-lives for each process in Table 1 .
Gratifyingly, not only does incorporation of the charged substituent at C-4 result in high initial affinity, but also, more importantly, it greatly reduces the rate constant for reactivation of enzymes inactivated by 2, 3, 4 and 5. Half-lives for reactivation of NAs labeled by 2, 3, 4 and 5 ranged from 0.75 h to >100 h. These very slow turnover rates are extremely important as they mean that the virus will remain inactivated for extended times, even after the compound may have been cleared from relevant tissues, with favorable consequences for pharmacokinetic behavior. Interestingly, compounds with an equatorial fluorine at C-3 inactivate and reactivate faster than do those with an axial fluorine, typically by 10-40 fold. Further, the presence of a guanidine substituent at C-4 slows both the inactivation and reactivation more than does an amine substituent, with a much greater effect on the reactivation step. Since the two transition states (for formation and hydrolysis) will be very similar, this difference in rate likely has its origins in optimized interactions of the guanidine with the active site at the stage of the covalent intermediate, as is seen in the crystal structure of the trapped species shown in Fig. 1C . A covalent bond of 1.45 Å is clearly observed in the electron density map (Fig. 1C, table S1 ), between C-2 of 3-fluoro (eq) sialic acid and the phenolic oxygen of Y406. As observed previously in a structure of the GH33 sialidase NanI (16), the covalent intermediate species is
accompanied by an unsaturated form of fluorosialic acid formed by elimination. The carboxylate groups of both bound species form electrostatic interactions with the guanidine groups of the strictly conserved arginine triad R118, R292 and R371, a key interaction common among existing NA inhibitors. However, the elimination product forms stronger interactions (≤3 Å) with R118 and R371 ( fig. S4 ) similar to those formed with zanamivir, while the covalent intermediate exhibits shorter contacts (≤3 Å) with R292 (Fig. 1D) . In addition to many other interactions that have been observed in previous complexes of N9 NA with zanamivir (17), both forms of
FeqGuDFSA also form electrostatic interactions at 2.9-3.4 Å (Fig. 1D and fig. S4 Table 2 , along with data for mutant viruses to be discussed below. Comparison between pairs of DFSAs again confirms that, in almost all cases, each compound with an equatorial fluorine is a superior inhibitor to its epimer with an axial fluorine, indicating that, under these conditions, improved rates of inactivation are important.
Likewise, in each case the guanidine derivative showed superior performance to its amine analogue. Consequently, compound 5 (FeqGuDFSA) was the optimal derivative within the series. Comparison of these IC 50 values with those for zanamivir and oseltamivir reveals that, on this measure, the compounds with an equatorial fluorine are of comparable efficacy, particularly when the guanidine is present. Further, their "on-rates" are superior to those of zanamivir, while off-rates are enormously slower (1, 20, 21) .
The specificity of these inhibitors was then evaluated by testing them against Neu2 as a representative human NA (all human NAs belong to the sequence-related family GH33). No inactivation of Neu2 was seen with either of the amine derivatives, and inactivation by FaxGuDFSA (3) and FeqGuDFSA (5) occurred slowly, but at rates some 10 5 -10 6 lower than seen for inactivation of NA at comparable concentrations. This behavior is a considerable improvement over zanamivir, which inhibits Neu2 with a K i of 17 M, only 10 3 -10 4 fold higher than for NA (22) .
Effects on influenza virus replication
Based upon these very promising results the ability of compounds 2 -5 to inhibit the replication of the virus in cell culture was explored using MDCK cells. Three A strains (N1, N2 and N9)
plus one B strain were tested in plaque size reduction assays (PRA), with zanamivir used as a control. While absolute sensitivity in the PRA depends on both the affinity of the HA for cell receptors as well as the NA function (23, 24) , it is a useful assay for determining relative sensitivity to inhibitors. The PRA data showed that all DFSAs inhibited virus replication (Table   3, Efficacy against resistant strains. The DFSA derivatives proved effective in vitro against a series of resistant strains, with the FeqGuDFSA (5) again proving to be the most widely active (Table 2 ). All compounds proved effective against virus with the H275Y mutation that affects binding of the isopentyl side chain of oseltamivir, as might be predicted. This is also reflected in the very similar kinetic data measured for each DFSA derivative with another H275Y
oseltamivir resistant strain and its parent (Table 1) . While the E119G mutation, which affects interactions with the inhibitor's guanidine (5), led to a 20-fold reduction in efficacy of In vivo efficacy studies.
Prior to in vivo efficacy studies in mouse models, the pharmacokinetic properties of FaxGuDFSA (3) as a representative DFSA derivative were evaluated for administration by intravenous and intranasal routes, and compared with data collected in parallel for zanamivir. Levels of 3 in blood, lung and trachea were measured and half-lives determined. Intranasal dosing resulted in 92% bioavailability compared to that seen with intravenous injection, along with approximately seven times higher peak concentrations (C max ) and ten times higher total exposure (AUC (0-120 min) )
in both lung and trachea compared to the intravenous route. Further, the plasma half-life of FaxGuDFSA (3) was also significantly longer after intranasal administration than after IV injection (table S2) . The general similarity of this pharmacokinetic behavior to that of zanamivir, consistent with the similar polarities of the two compounds, encouraged us to test the efficacy via intranasal administration, using zanamivir as our control.
Efficacy tests were conducted using a mouse-adapted influenza A virus strain, A/Hong Kong/1/68 (H3N2) (26) . Balb/c mice were treated with either DFSA derivative, zanamivir or saline twice daily by intranasal administration, starting two hours prior to infection. Body weights and general condition were monitored and when the animals lost 20% body weight they were euthanized and scored as non-survivors. In an initial study using 1 mg/kg/day of DFSA derivatives FaxGuDFSA showed superior results to FaxAmDFSA in prolonging the survival of animals. When FaxGuDFSA was tested at a higher dose of 10 mg/kg/day it protected all the mice from the lethal infection, as did zanamivir ( Fig. 2A) . In order to confirm that the compounds were acting as anti-viral agents, the viral RNA loads in lung tissue were measured by qPCR. These results confirmed that survival was indeed associated with suppression of viral replication, in a similar manner to the effect of zanamivir.
Dose-dependency of FeqGuDFSA in the protection of mice was demonstrated with 100% efficacy at 10 mg/kg/day and less protection at lower doses ( Fig. 2B and table S3 ). The compounds induced no ill-effect in the treated animals during the experiments compared to the saline control.
Conclusions
The DFSAs represent a novel class of potent, mechanism-based, specific NA inhibitor 
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